Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
- Takeda’s Japan Sales Ratio Falls Below 10%, Global Biz Thrives in H1
November 1, 2024
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Ono President Hopes to Turn Deciphera into Black in 2-3 Years
November 1, 2024
- Daiichi Sankyo Starts 3 Global PIII Trials of TROP2 ADC for NSCLC
November 1, 2024
- Kyowa Kirin Picks Abdul Mullick as New President and COO
November 1, 2024
- Otsuka Holdings Names Makoto Inoue as New CEO
November 1, 2024
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Mochida Bags Japan Rights to United Therapeutics’ Tyvaso DPI
November 1, 2024
- Tecentriq Filed for Rare Nasal Lymphoma in Japan: Chugai
November 1, 2024
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- iPark to Hold 1st US Investor Confab to Woo VCs for Asian Startups
October 31, 2024
- Orion Japan to Take Back Parkinson’s Drugs from Novartis
October 31, 2024
- Leqembi’s July-September Sales Up 1.6-Fold QOQ: Eisai
October 31, 2024
- 604 Employees Raise Hands for Sumitomo’s Buyout Program
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- Specialist Applauds Lilly’s Kisunla for Offering Treatment Goal
October 30, 2024
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Meiji Pharma to Discontinue Sales of Abilify Generics
October 30, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…